Chemistry:SpAMDA

From HandWiki

SpAMDA, also known as spiro-AMDA or as spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine, is a serotonin 5-HT2A receptor antagonist of the phenethylamine family.[1][2][3] It is a tricyclic and spiro cyclized phenethylamine and is an analogue of AMDA.[1][2][3]

The drug shows high affinity for the serotonin 5-HT2A receptor (Ki = 4 nM) and has 5-fold higher affinity than AMDA.[1][2][3] Its A2 value for serotonin 5-HT2A receptor antagonism is 79 nM.[2] In addition to the serotonin 5-HT2A receptor, SpAMDA shows 6-fold lower affinity for the serotonin 5-HT2C receptor (Ki = 24 nM), but no affinity for several other targets, such as the dopamine D2 receptor among others.[3]

The chemical synthesis of SpAMDA has been described.[2][3] Various analogues of SpAMDA have been described.[1][3]

SpAMDA was first described in the scientific literature by Richard Glennon and Bryan L. Roth and colleagues in 2003.[1][2][3]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 (in de) Phenethylamine: von der Struktur zur Funktion. Nachtschatten-Science (1 ed.). Solothurn: Nachtschatten-Verlag. 2013. ISBN 978-3-03788-700-4. OCLC 858805226. https://books.google.com/books?id=-Us1kgEACAAJ. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist". European Journal of Pharmacology 482 (1–3): 335–337. December 2003. doi:10.1016/j.ejphar.2003.09.059. PMID 14660041. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA)". Bioorganic & Medicinal Chemistry Letters 14 (9): 2279–2283. May 2004. doi:10.1016/j.bmcl.2004.02.014. PMID 15081025. Bibcode: 2004BMCL...14.2279P. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:SpAMDA&oldid=4433518"